OS2.8 Survival gain and immune response in glioblastoma patients treated with dendritic cell immunotherapy before and during adjuvant temozolomide

BACKGROUND: While immunotherapy is emerging as adjunctive treatment for brain cancer, sensitive method of monitoring the immune response after therapy remains to be established. In the two stage phase I-II study DENDR-I, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendri...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Pellegatta, S., Eoli, M., Anghileri, E., Frigerio, S., Cuccarini, V., Antozzi, C., Pollo, B., Pessina, S., Bruzzone, M., Finocchiaro, G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2016
Gaiak:
OS2 Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782518/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.018
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak